research: drug targets mutated P13k gene

Early results of a phase I study at Virginia G. Piper Cancer Center in Scottsdale, Arizona, collaborating with researchers at the Karmanos Cancer Institute in Detroit, Michigan, and the Dana-Farber Cancer Institute in Boston, Massachusetts, showed promise for a new drug that targets the P13k gene.

20- to 30-percent of patients with advanced breast cancer have the abnormal gene. The study of various advanced cancers, including breast, indicated that the new drug was successful in shrinking tumors with tolerable side effects.

Testing patients for the gene mutation is the next step in order to identify those who might benefit from treatment with the new drug, GDC-0941, manufactured by Genentech, San Francisco. Dr. Dr. Daniel D. Von Hoff presenting the findings at the annual conference of the American Society of Clinical Oncology (ASCO) in June 2011.

TGen, Virginia G. Piper Cancer Center studying new breast cancer drug 7-20-11

5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s